A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis

NCT01715896 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

215

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

BIOLOGICAL: Golimumab 50 mg
BIOLOGICAL: Mavrilimumab 100 mg

Sponsor

MedImmune LLC